What is LOPJLB’s current signal on RNTX?

LOPJLB’s latest quantitative signal on Rein Therapeutics Inc. (RNTX) is BUY in a RECOVERY regime. Signals are updated daily.

What market regime is RNTX in?

Rein Therapeutics Inc. (RNTX) is currently classified in the RECOVERY HMM market regime on LOPJLB.

Rein Therapeutics Inc. (RNTX)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$0.79+2.60%Close

BUYRECOVERY · day 1

RANGE

DATA 2026-10-09

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $22M
Beta: 1.35
P/E (TTM): -0.45

Short % float: 3.05%
Days to cover: 2.4
SI change: -2.9%

1W: -1.25%
1M: +1.28%

vs SPY 1W: -2.41%
vs SPY 1M: -1.71%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating…

Employees: 10
Headquarters: US
Founded: 2017
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 28.0M
Float: 76.4%

reintx.com ↗

Key executives

James Brian Windsor — Chief Executive Officer, President & Director

Timothy Cunningham — Interim Chief Financial Officer & Principal Accounting Officer

Ron Chen — Vice President of Finance and Corporate Controller

SEC filings

EDGAR · CIK 14205650 · RNTX

Analyst consensus

Buy

Bullish150.0%

Neutral150.0%

Bearish00.0%

L $6.00Avg $6.00H $6.00

Target$6.00+659.49%

Last$0.79

FAQ

What is LOPJLB’s current signal on RNTX?: LOPJLB’s latest quantitative signal on Rein Therapeutics Inc. (RNTX) is BUY in a RECOVERY regime. Signals are updated daily.
What market regime is RNTX in?: Rein Therapeutics Inc. (RNTX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does Rein Therapeutics Inc. (RNTX) do?: Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, …

Key stats

Prediction markets

Company news

FAQ